Tredence Acquires KMK Consulting to Expand Healthcare Analytics

Per a press release distributed via PR Newswire on June 22, 2026, Tredence announced it has acquired KMK Consulting, a specialized analytics and consulting firm headquartered in Morris Plains, New Jersey. The PR Newswire release says KMK "works with 8 of the world's top 10 Pharmaceutical companies" and brings more than two decades of life sciences expertise across commercial analytics, real world evidence (RWE), and market research. Inc42 reports that the financial terms of the transaction were not disclosed. The PR Newswire release states that Tredence expects Healthcare & Life Sciences (HLS) to become approximately 25% of its overall revenue by 2028, and cites a market estimate that the global market for AI in Life Sciences is expected to reach $69.3 billion by 2031. The release also says the acquisition strengthens Tredence's position within the Veeva ecosystem.

Editorial analysis: Companies combining domain consulting firms with applied-AI providers typically gain faster access to regulated datasets, curated feature sets, and platform integrations such as Veeva, which shifts engineering effort from raw ingestion toward compliance, validation, and model lifecycle controls. For practitioners, that pattern usually increases demand for robust RWE pipelines, privacy-preserving data engineering (deidentification, linkage, provenance), and reproducible evaluation frameworks for models that inform commercial and regulatory decisions.

Public reporting frames this acquisition as part of a broader trend where analytics vendors build specialized vertical stacks for life sciences to address commercial analytics, RWE, and launch optimization. The cited market estimate of $69.3 billion by 2031 underscores growing vendor and customer investment in AI for drug development, real-world studies, and commercial operations. Greater Veeva ecosystem alignment, as described in the release, is noteworthy because Veeva remains a dominant CRM/data platform in pharma and often acts as a practical integration point for commercial AI features.

Observers will watch for indicators of execution and integration: client retention among KMK customers, announced joint offerings or productized workflows for Molecule-to-Market analytics, public case studies showing compressed R&D-to-launch timelines, and any stated updates to revenue mix against the cited 25% by 2028 target. Practitioners should also follow how integrations with Veeva and RWE pipelines are operationalized, since those choices determine data access, governance, and model auditability.